New Data Show ACTOS Halted Progression of Atherosclerosis as Indicated by CIMT in Patients with Type 2 Diabetes
13th Nov 2006, 16:40 GMT
Results Demonstrated Significant Improvements on Cardiovascular Markers Beyond Glycemic Control
New Data Show ACTOS Halted Progression of Atherosclerosis as Indicated by CIMT in Patients with Type 2 Diabetes related news:
- New Data Show ACTOS(R) (pioglitazone HCl) Halted Progression of Atherosclerosis as Indicated by CIMT in Patients With Type 2 Diabetes — ArriveNet : Press Releases
- Takeda Pharmaceuticals North America: New Data Show ACTOS(R) (pioglitazone HCl) Halted Progression of Atherosclerosis as Indicated by CIMT in Patients With Type 2 Diabetes — Market Wire - Medical and Healthcare
- New data show ACTOS (pioglitazone HCl) halted progression of atherosclerosis as indicated by CIMT — EurekAlert! - Medicine and Health
- Study to Be Published in JAMA: Diabetes Drug ACTOS(R) (pioglitazone HCl) Halted Progression of Key Marker for Atherosclerosis; Improvements Indicated by Carotid Intima-Media Thickness (CIMT) — ArriveNet : Health
- OTSP: Study to Be Published in JAMA: Diabetes Drug ACTOS(R) (pioglitazone HCl) Halted Progression of Key Marker for Atherosclerosis; Improvements Indicated by Carotid Intima-Media Thickness (CIMT) — Market Wire - Medical and Healthcare
- AHA: Actos (pioglitazone) May Slow Progression of Atherosclerosis — MedPage Today.com Latest Headlines
- CHICAGO: Pioglitazone Slows Progression of Carotid Atherosclerosis vs Glimepiride — Medscape Med Students Headlines
- Diabetes drug may reduce cardiovascular risks — EurekAlert! - Medicine and Health
- Shed some Light on It — The Diabetes Blog
- Prevalence of Type 2 Diabetes in China Rivals That of US, Europe, and Japan Combined — Pharmaceuticals News from StratCenter.com
Latest news from Nephrology/ Dialysis News from StratCenter.com:
- Ruboxistaurin Reduced Vision Loss in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy in a New Study
- Aksys Reports Q3 2006 Financial Results
- Altus Pharmaceuticals Announces Presentation of ALTU-238 Phase II Data at Int'l Congress of Growth Hormone and Insulin-Like Growth Factor Research Societies
- Opexa Reports Q3 Financial Results
- Treatment of Diabetic Foot Ulcers Addressed at Upcoming American Heart Assoc Meeting
- Weight Loss Surgery Assists in Eliminating, Avoiding Type 2 Diabetes; American Institute of Gastric Banding Recognizes November as Nat'l Diabetes Month
- Federal Economic Development Agency Enlists Support of African-American Churches in the IL Delta
- Federal Economic Development Agency Enlists Support of African-American Churches in the MS Delta
- Federal Economic Development Agency Enlists Support of African-American Churches in the LA Delta
- Spherix Reports Q3 Earnings